Kiniksa Pharmaceuticals Stock Options
| KNSA Stock | USD 20.31 0.37 1.86% |
Kiniksa Pharmaceuticals' latest option contracts expiring on January 17th 2025 are carrying combined implied volatility of 0.35. The Kiniksa Pharmaceuticals option chain provides detailed quote and price information for the current Kiniksa Pharmaceuticals option contracts. It shows all of Kiniksa Pharmaceuticals' listed puts, calls, expiration dates, strike prices, and other pricing information.
Kiniksa Pharmaceuticals Maximum Pain Price Across 2025-01-17 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Kiniksa Pharmaceuticals close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, Kiniksa Pharmaceuticals' option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Kiniksa Pharmaceuticals
Analyzing Kiniksa Pharmaceuticals' in-the-money options over time can help investors to take a profitable long position in Kiniksa Pharmaceuticals regardless of its overall volatility. This is especially true when Kiniksa Pharmaceuticals' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Kiniksa Pharmaceuticals' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Kiniksa Pharmaceuticals' stock while costing only a fraction of its price.
Kiniksa Pharmaceuticals' stock options are financial instruments that give investors the right to buy or sell shares of Kiniksa Pharmaceuticals common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Kiniksa stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Kiniksa Pharmaceuticals' stock price goes up or down, the stock options follow.
At present, Kiniksa Pharmaceuticals' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Liabilities And Stockholders Equity is expected to grow to about 497.4 M, whereas Common Stock Total Equity is forecasted to decline to about 13.4 K. Kiniksa Current Options Market Mood
Kiniksa Pharmaceuticals' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Kiniksa Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Volume
Unfortunately, most Kiniksa Pharmaceuticals' options investors are not very successful. Kiniksa Pharmaceuticals' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Kiniksa contract
Base on the Rule 16, the options market is currently suggesting that Kiniksa Pharmaceuticals will have an average daily up or down price movement of about 0.0219% per day over the life of the 2025-01-17 option contract. With Kiniksa Pharmaceuticals trading at USD 20.31, that is roughly USD 0.004443. If you think that the market is fully incorporating Kiniksa Pharmaceuticals' daily price movement you should consider buying Kiniksa Pharmaceuticals options at the current volatility level of 0.35%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Kiniksa |
Purchasing Kiniksa Pharmaceuticals options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Kiniksa calls. Remember, the seller must deliver Kiniksa Pharmaceuticals stock to the call owner when a call is exercised.
Kiniksa Pharmaceuticals Option Chain
When Kiniksa Pharmaceuticals' strike price is surpassing the current stock price, the option contract against Kiniksa Pharmaceuticals stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Kiniksa Pharmaceuticals' option chain is a display of a range of information that helps investors for ways to trade options on Kiniksa. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Kiniksa. It also shows strike prices and maturity days for a Kiniksa Pharmaceuticals against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | KNSA250117C00005000 | 0 | 5.0 | 13.0 - 17.9 | 13.0 | |
Call | KNSA250117C00007500 | 0 | 7.5 | 10.6 - 15.5 | 10.6 | |
Call | KNSA250117C00010000 | 0 | 10.0 | 8.4 - 13.0 | 8.4 | |
Call | KNSA250117C00012500 | 0 | 12.5 | 6.2 - 11.0 | 6.2 | |
Call | KNSA250117C00015000 | 0 | 15.0 | 4.2 - 9.0 | 4.2 | |
Call | KNSA250117C00017500 | 0 | 17.5 | 2.5 - 7.3 | 2.5 | |
Call | KNSA250117C00020000 | 0 | 20.0 | 3.2 - 6.0 | 3.2 | |
Call | KNSA250117C00022500 | 0 | 22.5 | 0.1 - 5.0 | 0.1 | |
Call | KNSA250117C00025000 | 0 | 25.0 | 0.0 - 5.0 | 5.0 | |
Call | KNSA250117C00030000 | 0 | 30.0 | 0.0 - 5.0 | 5.0 | |
Put | KNSA250117P00005000 | 0 | 5.0 | 0.0 - 5.0 | 5.0 | |
Put | KNSA250117P00007500 | 0 | 7.5 | 0.0 - 5.0 | 5.0 | |
Put | KNSA250117P00010000 | 0 | 10.0 | 0.0 - 5.0 | 5.0 | |
Put | KNSA250117P00012500 | 0 | 12.5 | 0.0 - 5.0 | 5.0 | |
Put | KNSA250117P00015000 | 0 | 15.0 | 0.0 - 5.0 | 5.0 | |
Put | KNSA250117P00017500 | 0 | 17.5 | 0.0 - 5.0 | 5.0 | |
Put | KNSA250117P00020000 | 0 | 20.0 | 0.1 - 5.0 | 0.1 | |
Put | KNSA250117P00022500 | 0 | 22.5 | 1.6 - 6.5 | 1.6 | |
Put | KNSA250117P00025000 | 0 | 25.0 | 3.3 - 8.0 | 3.3 | |
Put | KNSA250117P00030000 | 0 | 30.0 | 7.6 - 12.5 | 7.6 |
Kiniksa Pharmaceuticals Market Cap Over Time
Market Cap |
| Timeline |
Kiniksa Total Stockholder Equity
Total Stockholder Equity |
|
Kiniksa Pharmaceuticals Corporate Management
| Madelyn Zeylikman | General SVP | Profile | |
| Melissa Manno | Senior Officer | Profile | |
| Ross Moat | Senior Officer | Profile | |
| Rachel Frank | Senior Communications | Profile | |
| Michael CPA | Chief Finance | Profile | |
| Chad Morin | Senior Officer | Profile |
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share | Quarterly Revenue Growth 0.674 | Return On Assets |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.